Amarin Corp. (AMRN) Achieves Topline Primary & Secondary Endpoint Results from REDUCE-IT, Cardiovascular Outcomes Trial for Vascepa (icosapent ethyl)
Tweet Send to a Friend
Amarin Corporation plc (NASDAQ: AMRN) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT™ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
